[1] Qurashi M, Vithayathil M, Khan S A. Epidemiology of cholangiocarcinoma[J]. Eur J Surg Oncol, 2025, 51(2): 107064.
[2] Tamandl D,Herberger B,Gruenberger B,et al. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol 2008, 15(10): 2787-2794.
[3] Bridgewater J,Fletcher P,Palmer D H,et al. Long-term outcomes and exploratory analyses of the randomized phase Ⅲ BILCAP Study[J]. J Clin Oncol, 2022, 40(18): 2048-2057.
[4] Lee A J, Chun Y S. Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates[J]. Chin Clin Oncol, 2018, 7(5): 52.
[5] Wang H, Chen J, Zhang X, et al. Expert consensus on pathological diagnosis of intrahepatic cholangiocarcinoma (2022 version)[J]. J Clin Transl Hepatol, 2023, 11(7): 1553-1564.
[6] Nagtegaal I D, Odze R D, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system[J]. Histopathology, 2020, 76(2): 182-188.
[7] Aishima S, Oda Y. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type[J]. J Hepatobiliary Pancreat Sci, 2015, 22(2): 94-100.
[8] Nepal C, O′Rourke C J , Oliveira D, et al. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma[J]. Hepatology, 2018, 68(3): 949-963.
[9] Lowery M A, Ptashkin R, Jordan E, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention[J]. Clin Cancer Res, 2018, 24(17): 4154-4161.
[10] Dong L Q, Lu D Y, Chen R, et al. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma[J]. Cancer Cell. 2022, 40(1): 70-87.
[11] Sia D, Hoshida Y, Villanueva, A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes[J]. Gastroenterology, 2013, 144(4): 829-840.
[12] Job S, Rapoud D, Santos A D, et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma[J]. Hepatology, 2020, 72(3): 965-981.
[13] Deng M J, Ran P, Chen L L, et al. Proteogenomic characterization of cholangiocarcinoma[J]. Hepatology, 2023, 77(2): 411-429.
[14] Lin Y, Peng L, Zhao H, et al. Robust transcriptomic hallmarks targeting intratumor heterogeneity in intrahepatic cholangiocarcinoma[J]. Cell Rep Med, 2026. 7(4): 102708.
[15] Martin-Serrano M, Kepecs B, Torres-Martin M, et al. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications[J]. Gut, 2023, 72(4): 736-748.
[16] Oh D Y, He A R, Bouattour, M, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study[J]. Lancet Gastroenterol Hepatol, 2024, 9(8): 694-704.
[17] Kelley R K, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2023, 401(10391): 1853-1865.
[18] Abou-Alfa G K, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2020, 21(5): 671-684.
[19] Zhu A X, Macarulla T, Javle M M, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial[J]. JAMA Oncol, 2021, 7(11): 1669-1677.
[20] Javle M, Borad M J, Azad N S, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multi-centre, open-label, phase 2a, multiple basket study[J]. Lancet Oncol, 2021, 22(9): 1290-1300.
[21] Ohba A, Morizane C, Kawamoto Y, et al. Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase Ⅱ trial[J]. J Clin Oncol, 2024, 42(27): 3207-3217.
[22] Harding J J, Fan J, Oh D Y, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study[J]. Lancet Oncol, 2023, 24(7): 772-782.
[23] Subbiah V S, Lassen U, Elez E, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial[J]. Lancet Oncol, 2020, 21(9): 1234-1243.
[24] Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial[J]. Lancet Oncol, 2022, 23(10): 1261-1273.
[25] Kim J, Bradford D, Larkins E, et al. FDA approval summary: pralsetinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions[J]. Clin Cancer Res, 2021, 27(20): 5452-5456.
[26] Malireddi R S, Kesavardhana S, Kanneganti T D. ZBP1 and TAK1: master regulators of NLRP3 inflammasome/pyroptosis, apoptosis, and necroptosis (PAN-optosis)[J]. Front Cell Infect Microbiol, 2019, 9: 406.
[27] Christgen S, Zheng M, Kesavardhana S, et al. Identification of the PANoptosome: a molecular platform triggering pyroptosis, apoptosis, and necroptosis (PANoptosis)[J]. Front Cell Infect Microbiol, 2020, 10: 237.
[28] Lee S, Karki R, Wang Y, et al. AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence[J]. Nature, 2021, 597(7876): 415-419.
[29] Malireddi R, Kesavardhana S, Karki R, et al. RIPK1 distinctly regulates yersinia-induced inflammatory cell death, PANoptosis[J]. Immunohorizons, 2020, 4(12): 789-796.
[30] Sundaram B, Pandian N, Mall R, et al. NLRP12-PANoptosome activates PANoptosis and pathology in response to heme and PAMPs[J]. Cell, 2023, 186(13): 2783-2801.e20.
[31] Sharma B R, Choudhury S M, Abdelaal H M, et al. Innate immune sensor NLRP3 drives PANoptosome formation and PANoptosis[J]. J Immunol, 2025, 214(6): 1236-1246.
[32] Sundaram B, Pandian N, Kim H J, et al. NLRC5 senses NAD(+) depletion, forming a PANoptosome and driving PANoptosis and inflammation[J]. Cell, 2024, 187(15): 4061-4077.e17.
[33] Chen B Y, Li L, Wang W Q, et al. Role of PANoptosis in cancer: double-edged sword effects and targeted therapies[J]. Int Immunopharmacol, 2026, 181: 116702.
[34] Li Y, Zhang H, Liu J, et al. The molecular mechanisms, roles, and potential applications of PANoptosis in cancer treatment[J]. Front Immunol, 2025, 16: 1550800.
[35] Wei S Y, Chen Z G, Ling X Y, et al. Comprehensive analysis illustrating the role of PANoptosis-related genes in lung cancer based on bioinformatic algorithms and experiments[J]. Front Pharmacol, 2023, 14: 1115221.
[36] Lin J F, Hu P S, Wang Y Y, et al. Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis[J]. Signal Transduct Target Ther, 2022, 7(1): 54.
[37] Liu L X, Heng J H, Deng D X, et al. Sulconazole induces PANoptosis by triggering oxidative stress and inhibiting glycolysis to increase radiosensitivity in esophageal cancer[J]. Mol Cell Proteomics, 2023, 22(6): 100551.
[38] Pan H, Pan J, Li P, et al. Characterization of PANoptosis patterns predicts survival and immunotherapy response in gastric cancer[J]. Clin Immunol, 2022, 238: 109019.
[39] Yu Y, You Y, Duan Y, et al. Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma[J]. Hepatology, 2026;83(2): 466-483. |
